FENC logo

Fennec Pharmaceuticals Inc. (FENC)

$12.76

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on FENC

Market cap

$453147370

EPS

-0.34

P/E ratio

--

Price to sales

6.34

Dividend yield

--

Beta

1.28843

Price on FENC

Previous close

$11.62

Today's open

$11.92

Day's range

$11.77 - $12.88

52 week range

$5.65 - $13.25

Profile about FENC

CEO

Jeffrey S. Hackman

Employees

29

Headquarters

Research Triangle Park, NC

Exchange

NASDAQ Capital Market

Shares outstanding

35305117

Issue type

Common Stock

FENC industries and sectors

Healthcare

Biotechnology & Life Sciences

News on FENC

Adherex Technologies (FENC) is on the Move, Here's Why the Trend Could be Sustainable

Adherex Technologies (FENC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

news source

Zacks Investment Research • 20 hours ago

news preview

How Much Upside is Left in Adherex Technologies (FENC)? Wall Street Analysts Think 57.8%

The consensus price target hints at a 57.8% upside potential for Adherex Technologies (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • Nov 13, 2026

news preview

What Makes Adherex Technologies (FENC) a New Strong Buy Stock

Adherex Technologies (FENC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

news source

Zacks Investment Research • Nov 13, 2026

news preview

Adherex Technologies Q3 Earnings Call Highlights

Fennec Pharmaceuticals NASDAQ: FENC reported third-quarter net product sales of $19.4 million, up 56% from a year earlier, as use of its hearing-protection drug PEDMARK expanded among new and existing customers.

news source

MarketBeat • Nov 12, 2026

news preview

Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (FENC) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 12, 2026

news preview

Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

~ Third Quarter 2026 Net Product Sales of $19.4 Million, Up 56% Year over Year ~ ~ Third Quarter 2026 Non-GAAP Adjusted EBITDA of $5.8 Million ~ ~ With $6.7 Million in Positive Cash Flow from Operations, Cash Position in the Third Quarter 2026 Grew to $48.7 Million ~ ~ Record Number of Patients and Planned Infusions Carried into the Fourth Quarter 2026 ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.

news source

GlobeNewsWire • Nov 12, 2026

news preview

Adherex Technologies Inc. (FENC) Q3 Earnings and Revenues Beat Estimates

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.02 per share a year ago.

news source

Zacks Investment Research • Nov 12, 2026

news preview

Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, November 12, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.

news source

GlobeNewsWire • Nov 6, 2026

news preview

Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026

~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~

news source

GlobeNewsWire • Sep 17, 2026

news preview

Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

news source

Zacks Investment Research • Aug 12, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Fennec Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Fennec Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in FENC on M1